Allogeneic mouse antilymphocyte serum effectively reduced the number of antibody plaque-forming cells after the natural antilytic property had been eliminated by dilution.
There is a paucity of inlformation in literature documenting the properties of allogeneic antilymphocyte serum (ALS). Several studies of allogeneic ALS have been reported (1, 3, 4, 6, 8, 9) . In view of the antigenicity of heterologous ALS preparations, and since ALS therapy in some cases is continued over a period of time, it seems relevant to investigate the immunosuppressive activity of allogeneic antilymphocyte sera. Of importance, perhaps, is the advantage the allogeneic system could offer as a model for studying the mode of action of ALS preparations. This paper reports the in vitro reduction of antibody plaque-forming cells (PFC) by allogeneic mouse ALS and the presence of an antilytic property of normal mouse sera (nonimmunized).
C57B1/6N and BALB/cAnN female mice from the Laboratory Aids Branch, National Institutes of Health, were used. These two strains of mice differ at the H-2 locus (H-2b and H-2d, respectively) and also at the H-1, H-3, and H-7 loci (7).
BALB/c anti-C57BI-lymphocyte sera aind C57B1 anti-BALB/c-lymphocyte sera were prepared by injecting C57B1 or BALB/c spleen cells into reciprocal mouse strains. One-milliliter injections of approximately 109 cells were given intraperitoneally and the mice were bled 11 days later. Sera were collected and stored at -70 C. Sera pooled from two or more mice were used as individual ALS preparations. Prior to assay the sera were heat inactivated (56 C for 30 min).
Spleen cell suspensions for use in the antibody plaque-forming assay were prepared from spleens of mice immunized intraperitoneally with 1 ml of 10% washed sheep red blood cells (SRBC). The whole spleen was placed immediately after extirpation into Hanks balanced salt solution containing 15% fetal calf serum. This buffer was used for preparation of spleen cells which were to be assayed in the antibody plaqueforming assay. Spleen cells for injection to obtain ALS were prepared employing only Hanks balanced salt solution with no fetal calf serum. Free cell suspensions were obtained by shaking slightly minced spleeni tissue in buffer, straining through fine mesh stainless steel sieves, and washing three times. Cell counts were determined and appropriate dilutions were made. Pooled sera from two or more mice were used as individual ALS preparations.
The antibody plaque-forming assay was performed on glass microscope slides under cover slips (2) utilizing spleen cells from SRBC-immunized mice, BALB/c anti-C57BI ALS or C57B1 anti-BALB/c ALS, and guinea pig serum as a source of complement. Plaques were counted and the number of PFC/106 spleen cells were determined by the following formula: PFC/106 = (Number of plaques counted X dilution factor of spleen cells)/(Volume under cover slip in milliliters X millions of cells per milliliter).
Results of preliminary trials indicated that the two strains of mice used in this study differed consistently in the amount of time required following primary immunization to mount an antibody plaque-forming response to SRBC. BALB/c mice exhibited peak numbers of plaqueforming cells 4 Whereas cytotoxicity titers were niot determiiied for each of the sera used, those ALS which were tested for cytotoxicity by a 5'Cr release 
